placeholder image
Michael H. Rosenbloom, MD
Former Director, Center for Memory and Aging

Joined the Institute: 2010

Education and training: MD, Columbia University, College of Physicians and Surgeons

Overview/research interests: Pittsburgh Compound B imaging in atypical presentations of Alzheimer’s disease, rapidly progressive dementia, early diagnosis of Alzheimer’s disease, intranasal insulin in Alzheimer’s Disease, cognitive screening.

Current research activities and funding:

  • Principal investigator (PI) for A Double-Blinded, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed with Probable Mild to Moderate Alzheimer’s Disease/Intranasal Insulin Study
  • PI for “Feasibility of the Mini-Cog as a Standardized Cognitive Screen in HealthPartners Patients Aged 70 and Older”
  • PI for “A Phase 3 Randomized, Double-Blind Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human) 10% Solution (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease (AD)”
Publications While At HealthPartners
selected publications
Journal Article
  • Left dural carotid cavernous fistula mimicking an inflammatory process: a case report
    Radiology case reports. 2024
  • A case of minimally progressive prodromal Alzheimer's disease
    Journal of Alzheimer's disease reports. 2023
  • Abnormal clinical presentation and surgical outcome of an intraventricular cavernoma of the third ventricle
    BMJ Case Reports. 2023
  • Implementation and review of the care ecosystem in an integrated healthcare system
    BMC Geriatrics. 2023
  • Prodromal dementia with Lewy bodies: evolution of symptoms and predictors of dementia onset
    Journal of Geriatric Psychiatry and Neurology. 2022
  • Responding to the needs of persons living with dementia and their caregivers during the COVID-19 pandemic: lessons from the Care Ecosystem
    Innovation in aging. 2022
  • A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer's disease
    Drugs and Aging. 2021
  • Double-blind placebo-controlled pilot investigation of the safety of a single dose of rapid-acting intranasal insulin in Down syndrome
    Drugs in R&D. 2020
  • Screening positive for cognitive impairment: impact on healthcare utilization and provider action in primary and specialty care practices
    Journal of General Internal Medicine. 2018
  • NMDA receptor antibody encephalitis presenting with enhancing lesion and seizures
    Neurology. Clinical practice. 2017
  • Routine cognitive screening in a neurology practice: effect on physician behavior
    Neurology. Clinical practice. 2016
  • Susac syndrome with prominent dermatological findings and a prompt response to intravenous immunoglobulin, steroids, and rituximab: a case report
  • Metabolic disorders with clinical and radiologic features of sporadic Creutzfeldt-Jakob disease
    Neurology. Clinical practice. 2015
  • A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein e4 carriers with mild-moderate Alzheimer's disease
    CNS drugs. 2014
  • The functional neuroanatomy of decision-making
    Journal of Neuropsychiatry and Clinical Neurosciences. 2012
  • Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution
    Neurology. 2011
  • Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil
    Consultant Pharmacist. 2011
  • Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB)
    Alzheimer Disease and Associated Disorders. 2010
  • Chapter
  • Comportment: structure and function
    Neurology and Neuropsychiatry. 2013
  • Contact
    full name
  • Michael H. Rosenbloom, MD
  • located in facility
    Quick Info